市場調査レポート

商品コード

1803145

幻覚剤マイクロドージングの世界市場：将来予測 (2032年まで) - 成分別・投与経路別・流通チャネル別・用途別・地域別の分析

Psychedelic Microdosing Market Forecasts to 2032 - Global Analysis By Component (Psilocybin, Ketamine, MDMA and Other Compounds), Route of Administration, Distribution Channel, Application and By Geography

出版日: 2025年09月07日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 619,387円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 783,562円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 947,737円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,119,375円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.25円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の幻覚剤マイクロドージング市場は、2025年に21億米ドルを占め、予測期間中にCAGR 15％で成長し、2032年までに58億米ドルに達すると予想されています。

幻覚剤マイクロドージングとは、LSDやシロシビンなどのサイケデリック物質を非常に少量、知覚以下の量で摂取することを指し、通常、娯楽用量の10分の1から20分の1程度です。幻覚や強烈な知覚の変化を引き起こす完全なサイケデリック体験とは異なり、マイクロドージングは、日常機能を著しく損なうことなく、微妙な認知的、感情的、生理的な恩恵をもたらすことを目的としています。マイクロドージングは、創造性、集中力、気分の安定性、感情的な幸福感を高めると同時に、不安や抑うつ症状を軽減する可能性があると提唱者は指摘しています。潜在的なメンタルヘルス効果や生産性向上効果により人気が高まっているが、その安全性、有効性、長期的効果に関する科学的調査はまだ限られており、現在も進行中です。

新しいメンタルヘルス治療に対する需要の高まり

うつ病、不安神経症、PTSDの有病率の上昇により、従来の治療法の欠点が露呈しています。幻覚剤マイクロドージングは、気分を高揚させ、集中力を研ぎ澄まし、副作用を抑えながら精神的な幸福を促進する能力があるとして注目を集めています。社会的認知の高まりと肯定的な臨床所見とが相まって、患者にも医療関係者にも受け入れられつつあります。この機運は、安全で規制されたサイケデリック療法の開発への投資を後押ししています。その結果、市場は急速に拡大し、利用が広がっています。

マイクロドージングに関する質の高い臨床エビデンスは限られている

確実な臨床試験がないため、規制当局はマイクロドージングに対する承認や支援に慎重です。検証が不十分なため、投資家の信頼も低下し、研究や商業化のための資金援助も制限されます。科学的実証が限られているため、ヘルスケア専門家がマイクロドーズの使用を薦めるのをさらに躊躇させています。そのため、消費者への普及は遅々として進まず、臨床的検証よりもむしろ、主として逸話的経験によって形成されています。ひいては、信頼できるエビデンスの不足が市場の拡大を妨げ、より広く受け入れられるのを遅らせています。

新しい製品形態と流通チャネル

カプセル、グミ、点鼻スプレー、舌下ストリップなどの革新的な製品形態は、便利で正確な服用を可能にします。こうした形態は、マイクロドージングをより親しみやすく、汚名を着せにくいものにすることで、より幅広い消費者層にアピールします。オンライン・プラットフォーム、遠隔医療サービス、ウェルネス・クリニックは、控えめで安全なアクセスを提供することで、流通をさらに強化します。小売店との提携やデジタル・マーケットプレースも、知名度と消費者の信頼を高めるのに役立っています。これらの進歩が相まって、より広範な普及と市場成長が促進されます。

規制と法的障壁

多くの国では厳格な薬物分類法により、サイケデリックの研究、臨床試験、治療への応用が制限されています。長い承認プロセスと複雑なコンプライアンス要件が、新規参入企業の技術革新と市場参入を遅らせています。世界的に統一された規制がないため、国境を越えた協力や拡大がさらに制限されます。法的影響への懸念が、この分野への投資や事業開発を妨げます。全体として、こうした障壁が採用を遅らせ、市場の成長可能性を制限しています。

COVID-19の影響

COVID-19の大流行は、幻覚剤マイクロドージング市場にさまざまな影響を与えました。一方では臨床試験や研究が制限され、製品開発や規制の進展が遅れました。サプライチェーンの混乱は、原料へのアクセスやサイケデリックに基づく製品の供給にも影響を与えました。しかし、パンデミックは不安、うつ、ストレスといった精神衛生上の課題を増大させ、マイクロドーズのような代替療法への関心の高まりにつながりました。遠隔医療やデジタル・メンタルヘルス・プラットフォームへのシフトは、この期間、幻覚剤マイクロドージングに関する認識や議論をさらに後押ししました。

予測期間中、シロシビン・セグメントが最大となる見込み

シロシビン・セグメントは、メンタルヘルス研究と治療における受容の拡大により、予測期間中に最大の市場シェアを占めると予想されます。うつ病、不安症、PTSDの治療におけるシロシビンの有効性を強調する臨床研究が増加しており、制御されたマイクロドーズへの需要が高まっています。天然サイケデリックに対する社会的認知の高まりとスティグマ（烙印）の軽減が、さらに採用を後押ししています。さらに、一部の地域では規制機関が規制を緩和しており、商業的応用の機会が広がっています。全体として、シロシビンの強力な治療可能性と認識の変化が、市場の主要な成長促進要因となっています。

認知機能強化分野は予測期間中に最も高いCAGRが見込まれる

予測期間中、認知機能強化分野は、集中力、創造性、生産性の向上を求める人々を惹きつけ、最も高い成長率を記録すると予測されます。専門家、学生、起業家の関心の高まりは、マイクロドージングが精神的なパフォーマンスを最適化するためのツールと見なされるようになり、需要を促進しています。問題解決力や記憶保持力の向上といった利点を強調する科学的研究や逸話的証拠が、市場の採用をさらに強化しています。また、向精神薬とウェルネス動向の融合が進んでいることも、マイクロドージングを主流にしています。全体として、認知機能の強化は、マイクロドージングをパフォーマンスを高めるライフスタイルの選択肢として位置づけることで、重要な推進力として機能しています。

最大シェアの地域

予測期間中、メンタルヘルスに対する意識の高まりと代替療法に対する社会的態度の変化により、北米地域が最大の市場シェアを占めると予想されます。研究、臨床試験、新興企業エコシステムへの投資が増加し、製品の革新と開発が加速しています。ウェルネスと個人の生産性をめぐる世論が需要をさらに強めています。米国の特定の州やカナダの地域では、規制の先進的なシフトを促進する支援的なイニシアチブがあり、よりオープンな環境が構築されています。しかし、法的な不確実性とスティグマは依然として課題ですが、消費者の関心と制度的な後ろ盾は引き続き市場の成長を後押ししています。

CAGRが最も高い地域：

予測期間中、欧州地域が最も高いCAGRを示すと予測されますが、これはウェルネス・コミュニティ、メンタルヘルス専門家、研究機関からの強い関心によるものです。不安、うつ、認知能力に対する代替治療に対する意識の高まりが需要を形成しています。規制は国によってまちまちで、チャンスと障壁の両方を生み出しています。学術研究や臨床試験が信頼性を高める一方、ウェルネス・ツーリズムやライフスタイルの動向も好奇心を煽ります。ホリスティックな健康法が文化的に受け入れられていることも普及を後押ししていますが、いくつかの国では法的枠組みが厳しく、より広範な商業化が遅れています。

無料のカスタマイズサービス

当レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域区分
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東・アフリカ

第10章主な動向

契約、事業提携・協力、合弁事業
企業合併・買収 (M&A)
新製品の発売
事業拡張
その他の主要戦略

第11章企業プロファイリング

COMPASS Pathways
MindMed Inc.
Cybin Inc.
Atai Life Sciences
Beckley Psytech
Seelos Therapeutics
Delix Therapeutics
Eleusis
GH Research PLC
Awakn Life Sciences
Numinus Wellness
Mydecine Innovations Group
Entheon Biomedical
Wesana Health
Tryp Therapeutics
Enveric Biosciences
Clairvoyant Therapeutics

図表

List of Tables

Table 1 Global Psychedelic Microdosing Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
Table 3 Global Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
Table 4 Global Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
Table 5 Global Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
Table 6 Global Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
Table 7 Global Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
Table 8 Global Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 9 Global Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
Table 10 Global Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
Table 11 Global Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
Table 12 Global Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
Table 13 Global Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
Table 14 Global Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 15 Global Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
Table 16 Global Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
Table 17 Global Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
Table 18 Global Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
Table 19 Global Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
Table 20 Global Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
Table 21 Global Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
Table 22 Global Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
Table 23 Global Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
Table 24 Global Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
Table 25 North America Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
Table 26 North America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
Table 27 North America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
Table 28 North America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
Table 29 North America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
Table 30 North America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
Table 31 North America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
Table 32 North America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 33 North America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
Table 34 North America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
Table 35 North America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
Table 36 North America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
Table 37 North America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
Table 38 North America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 39 North America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
Table 40 North America Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
Table 41 North America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
Table 42 North America Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
Table 43 North America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
Table 44 North America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
Table 45 North America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
Table 46 North America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
Table 47 North America Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
Table 48 North America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
Table 49 Europe Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
Table 50 Europe Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
Table 51 Europe Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
Table 52 Europe Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
Table 53 Europe Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
Table 54 Europe Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
Table 55 Europe Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
Table 56 Europe Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 57 Europe Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
Table 58 Europe Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
Table 59 Europe Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
Table 60 Europe Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
Table 61 Europe Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
Table 62 Europe Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 63 Europe Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
Table 64 Europe Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
Table 65 Europe Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
Table 66 Europe Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
Table 67 Europe Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
Table 68 Europe Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
Table 69 Europe Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
Table 70 Europe Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
Table 71 Europe Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
Table 72 Europe Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
Table 73 Asia Pacific Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
Table 74 Asia Pacific Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
Table 75 Asia Pacific Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
Table 76 Asia Pacific Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
Table 77 Asia Pacific Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
Table 78 Asia Pacific Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
Table 79 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
Table 80 Asia Pacific Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 81 Asia Pacific Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
Table 82 Asia Pacific Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
Table 83 Asia Pacific Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
Table 84 Asia Pacific Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
Table 85 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
Table 86 Asia Pacific Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 87 Asia Pacific Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
Table 88 Asia Pacific Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
Table 89 Asia Pacific Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
Table 90 Asia Pacific Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
Table 91 Asia Pacific Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
Table 92 Asia Pacific Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
Table 93 Asia Pacific Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
Table 94 Asia Pacific Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
Table 95 Asia Pacific Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
Table 96 Asia Pacific Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
Table 97 South America Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
Table 98 South America Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
Table 99 South America Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
Table 100 South America Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
Table 101 South America Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
Table 102 South America Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
Table 103 South America Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
Table 104 South America Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 105 South America Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
Table 106 South America Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
Table 107 South America Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
Table 108 South America Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
Table 109 South America Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
Table 110 South America Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 111 South America Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
Table 112 South America Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
Table 113 South America Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
Table 114 South America Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
Table 115 South America Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
Table 116 South America Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
Table 117 South America Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
Table 118 South America Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
Table 119 South America Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
Table 120 South America Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)
Table 121 Middle East & Africa Psychedelic Microdosing Market Outlook, By Country (2024-2032) ($MN)
Table 122 Middle East & Africa Psychedelic Microdosing Market Outlook, By Compound (2024-2032) ($MN)
Table 123 Middle East & Africa Psychedelic Microdosing Market Outlook, By Psilocybin (2024-2032) ($MN)
Table 124 Middle East & Africa Psychedelic Microdosing Market Outlook, By LSD (2024-2032) ($MN)
Table 125 Middle East & Africa Psychedelic Microdosing Market Outlook, By Ketamine (2024-2032) ($MN)
Table 126 Middle East & Africa Psychedelic Microdosing Market Outlook, By MDMA (2024-2032) ($MN)
Table 127 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Compounds (2024-2032) ($MN)
Table 128 Middle East & Africa Psychedelic Microdosing Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 129 Middle East & Africa Psychedelic Microdosing Market Outlook, By Oral (2024-2032) ($MN)
Table 130 Middle East & Africa Psychedelic Microdosing Market Outlook, By Sublingual (2024-2032) ($MN)
Table 131 Middle East & Africa Psychedelic Microdosing Market Outlook, By Nasal (2024-2032) ($MN)
Table 132 Middle East & Africa Psychedelic Microdosing Market Outlook, By Transdermal (2024-2032) ($MN)
Table 133 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
Table 134 Middle East & Africa Psychedelic Microdosing Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 135 Middle East & Africa Psychedelic Microdosing Market Outlook, By Prescription (2024-2032) ($MN)
Table 136 Middle East & Africa Psychedelic Microdosing Market Outlook, By Direct-to-consumer (2024-2032) ($MN)
Table 137 Middle East & Africa Psychedelic Microdosing Market Outlook, By Research supply (2024-2032) ($MN)
Table 138 Middle East & Africa Psychedelic Microdosing Market Outlook, By Application (2024-2032) ($MN)
Table 139 Middle East & Africa Psychedelic Microdosing Market Outlook, By Mental health (2024-2032) ($MN)
Table 140 Middle East & Africa Psychedelic Microdosing Market Outlook, By Cognitive enhancement (2024-2032) ($MN)
Table 141 Middle East & Africa Psychedelic Microdosing Market Outlook, By Wellness and lifestyle (2024-2032) ($MN)
Table 142 Middle East & Africa Psychedelic Microdosing Market Outlook, By Addiction treatment (2024-2032) ($MN)
Table 143 Middle East & Africa Psychedelic Microdosing Market Outlook, By Home use (2024-2032) ($MN)
Table 144 Middle East & Africa Psychedelic Microdosing Market Outlook, By Other Applications (2024-2032) ($MN)

Product Code: SMRC30670

According to Stratistics MRC, the Global Psychedelic Microdosing Market is accounted for $2.1 billion in 2025 and is expected to reach $5.8 billion by 2032 growing at a CAGR of 15% during the forecast period. Psychedelic microdosing refers to the practice of consuming very small, sub-perceptual doses of psychedelic substances such as LSD or psilocybin, typically around one-tenth to one-twentieth of a recreational dose. Unlike full psychedelic experiences that cause hallucinations and intense alterations in perception, microdosing aims to deliver subtle cognitive, emotional, and physiological benefits without significantly impairing daily functioning. Advocates suggest that microdosing may enhance creativity, focus, mood stability, and emotional well-being, while reducing anxiety or depression symptoms. Although gaining popularity for potential mental health and productivity benefits, scientific research on its safety, efficacy, and long-term effects remains limited and ongoing.

Market Dynamics:

Driver:

Rising demand for new mental-health treatments

The rising prevalence of depression, anxiety, and PTSD has exposed the shortcomings of conventional treatments. Microdosing psychedelics is gaining attention for its ability to elevate mood, sharpen focus, and promote mental well-being with reduced adverse effects. Increasing public awareness combined with positive clinical findings is fostering greater acceptance among both patients and medical professionals. This momentum is driving investments in the development of safe, regulated psychedelic therapies. Consequently, the market is experiencing rapid expansion and wider utilization.

Restraint:

Limited high-quality clinical evidence for microdosing

Lack of robust clinical trials makes regulatory authorities cautious about granting approval or support for microdosing. Insufficient validation also diminishes investor trust and limits financial backing for research and commercialization. Limited scientific proof further discourages healthcare professionals from recommending its use. Consumer adoption therefore remains slow and is primarily shaped by anecdotal experiences rather than clinical validation. In turn, the shortage of reliable evidence hinders market expansion and delays wider acceptance.

Opportunity:

New product formats & distribution channels

Innovative product forms such as capsules, gummies, nasal sprays, and sublingual strips offer convenient and precise dosing. These formats appeal to a wider consumer base by making microdosing more approachable and less stigmatized. Online platforms, telehealth services, and wellness clinics further enhance distribution by providing discreet and safe access. Retail partnerships and digital marketplaces also help increase visibility and consumer trust. Together, these advancements drive broader adoption and market growth.

Threat:

Regulatory & legal barriers

Strict drug classification laws in many countries restrict research, clinical trials, and therapeutic applications of psychedelics. Lengthy approval processes and complex compliance requirements slow down innovation and market entry for new players. The lack of harmonized global regulations further limits cross-border collaboration and expansion. Fear of legal repercussions discourages investment and business development in the sector. Overall, these barriers delay adoption and restrict the market's growth potential.

Covid-19 Impact

The Covid-19 pandemic had a mixed impact on the psychedelic microdosing market. On one hand, restrictions on clinical trials and research slowed product development and regulatory progress. Supply chain disruptions also affected access to raw materials and delivery of psychedelic-based products. However, the pandemic increased mental health challenges such as anxiety, depression, and stress, leading to growing interest in alternative therapies like microdosing. The shift toward telemedicine and digital mental health platforms further supported awareness and discussions around psychedelic microdosing during this period.

The psilocybin segment is expected to be the largest during the forecast period

The psilocybin segment is expected to account for the largest market share during the forecast period, due to its growing acceptance in mental health research and therapy. Increasing clinical studies highlight psilocybin's effectiveness in treating depression, anxiety, and PTSD, driving demand for controlled microdosing. Rising public awareness and reduced stigma around natural psychedelics further encourage adoption. Additionally, regulatory bodies in some regions are easing restrictions, opening opportunities for commercial applications. Overall, psilocybin's strong therapeutic potential and shifting perceptions make it a key growth driver for the market.

The cognitive enhancement segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cognitive enhancement segment is predicted to witness the highest growth rate by attracting individuals seeking improved focus, creativity, and productivity. Rising interest from professionals, students, and entrepreneurs fuels demand as microdosing is increasingly viewed as a tool for mental performance optimization. Scientific studies and anecdotal evidence highlighting benefits like better problem-solving and memory retention further strengthen market adoption. The growing integration of nootropics and wellness trends also aligns with the microdosing movement, making it more mainstream. Overall, cognitive enhancement acts as a key driver by positioning microdosing as a performance-boosting lifestyle choice.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to rising mental health awareness and shifting societal attitudes toward alternative therapies. Increasing investment in research, clinical trials, and startup ecosystems is accelerating product innovation and development. Public discourse around wellness and personal productivity further strengthens demand. Supportive initiatives in certain U.S. states and Canadian regions foster progressive regulatory shifts, creating a more open environment. However, legal uncertainties and stigma remain challenges, though consumer interest and institutional backing continue to push market growth.

Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR, owing to strong interest from wellness communities, mental health practitioners, and research organizations. Growing awareness of alternative treatments for anxiety, depression, and cognitive performance is shaping demand. Regulations are mixed across countries, creating both opportunities and barriers. Academic studies and clinical trials drive credibility, while wellness tourism and lifestyle trends also fuel curiosity. The cultural acceptance of holistic health practices supports adoption, though stricter legal frameworks in several nations slow down wider commercialization.

Key players in the market

Some of the key players profiled in the Psychedelic Microdosing Market include COMPASS Pathways, MindMed Inc., Cybin Inc., Atai Life Sciences, Beckley Psytech, Seelos Therapeutics, Delix Therapeutics, Eleusis, GH Research PLC, Awakn Life Sciences, Numinus Wellness, Mydecine Innovations Group, Entheon Biomedical, Wesana Health, Tryp Therapeutics, Enveric Biosciences, and Clairvoyant Therapeutics.

Key Developments:

In April 2025, Cybin secured Strategic Partnership Agreements with 18 clinical sites for its Phase 3 CYB003 program. These collaborations aim to streamline operations, boost patient recruitment, and standardize protocols across the PARADIGM trial's multinational infrastructure.

In February 2024, MindMed partnered with Sphere Health to advance digital biomarkers and remote monitoring for psychedelic therapies, including microdosing. The collaboration integrates wearable tech with clinical protocols to enhance patient tracking, dose-response analysis, and personalized treatment optimization.

In January 2024, COMPASS entered a three-year research collaboration with Greenbrook TMS to pilot COMP360 psilocybin therapy across U.S. clinics. The initiative targets treatment-resistant depression, optimizing therapist workflows, patient experience, and digital integration for scalable delivery.

Compounds Covered:

Psilocybin
LSD
Ketamine
MDMA
Other Compounds

Route of Administrations Covered:

Oral
Sublingual
Nasal
Transdermal
Other Route of Administrations

Distribution Channels Covered:

Prescription
Direct-to-consumer
Research supply

Applications Covered:

Mental health
Cognitive enhancement
Wellness and lifestyle
Addiction treatment
Home use
Other Applications

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Psychedelic Microdosing Market, By Compound

5.1 Introduction
5.2 Psilocybin
5.3 LSD
5.4 Ketamine
5.5 MDMA
5.6 Other Compounds

6 Global Psychedelic Microdosing Market, By Route of Administration

6.1 Introduction
6.2 Oral
6.3 Sublingual
6.4 Nasal
6.5 Transdermal
6.6 Other Route of Administrations

7 Global Psychedelic Microdosing Market, By Distribution Channel

7.1 Introduction
7.2 Prescription
7.3 Direct-to-consumer
7.4 Research supply

8 Global Psychedelic Microdosing Market, By Application

8.1 Introduction
8.2 Mental health
8.3 Cognitive enhancement
8.4 Wellness and lifestyle
8.5 Addiction treatment
8.6 Home use
8.7 Other Applications

9 Global Psychedelic Microdosing Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 COMPASS Pathways
11.2 MindMed Inc.
11.3 Cybin Inc.
11.4 Atai Life Sciences
11.5 Beckley Psytech
11.6 Seelos Therapeutics
11.7 Delix Therapeutics
11.8 Eleusis
11.9 GH Research PLC
11.10 Awakn Life Sciences
11.11 Numinus Wellness
11.12 Mydecine Innovations Group
11.13 Entheon Biomedical
11.14 Wesana Health
11.15 Tryp Therapeutics
11.16 Enveric Biosciences
11.17 Clairvoyant Therapeutics

幻覚剤マイクロドージングの世界市場：将来予測 (2032年まで) - 成分別・投与経路別・流通チャネル別・用途別・地域別の分析

Psychedelic Microdosing Market Forecasts to 2032 - Global Analysis By Component (Psilocybin, Ketamine, MDMA and Other Compounds), Route of Administration, Distribution Channel, Application and By Geography

最大シェアの地域

CAGRが最も高い地域：

無料のカスタマイズサービス

当レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序論

第3章 市場動向の分析

第4章 ポーターのファイブフォース分析

第5章 世界の幻覚剤マイクロドージング市場：成分別

第6章 世界の幻覚剤マイクロドージング市場：投与経路別

第7章 世界の幻覚剤マイクロドージング市場：流通チャネル別

第8章 世界の幻覚剤マイクロドージング市場：用途別

第9章 世界の幻覚剤マイクロドージング市場：地域別

第10章 主な動向

第11章 企業プロファイリング